UK trial finds no benefit from azithromycin in hospital COVID-19 patientsInvestigators with the United Kingdom's RECOVERY trial reported yesterday that a preliminary analysis of data from the azithromycin arm of the trial showed the antibiotic had no impact on clinical outcomes in hospitalized COVID-19 patients.In the trial, which was conducted among COVID-19 patients at 176 National Health Service hospitals, 2,582 patients were randomized to receive 500 milligrams of azithromycin, an antibiotic, once daily and compared with 5,182 patients who received usual care.
Patients entered the study an average of 8 days after onset of symptoms. The primary outcome was 28-day mortality, and the results, which were not peer-reviewed, were published on